Enterprise Value

54.23M

Cash

142.8M

Avg Qtr Burn

-7.582M

Short % of Float

4.48%

Insider Ownership

2.01%

Institutional Own.

60.64%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Reproxalap Details
Dry eye syndrome

NDA

Resubmission

ADX-2191 (methotrexate injection (DHFR inhibitor)) Details
Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma, Retinitis Pigmentosa

NDA

FDA meeting

Reproxalap (ADX-102) Details
Rare diseases, Rare genetic disease, Allergic conjunctivitis

Phase 3

Update

ADX-629 Details
Alcoholic hepatitis, Liver disease

Phase 2

Data readout

ADX-629 Details
Sjögren-Larsson Syndrome

Phase 2

Update

ADX-629 Details
Chronic cough

Phase 2

Update

ADX-629 Details
Idiopathic Nephrotic Syndrome

Phase 2a

Data readout

ADX-629 Details
Atopic dermatitis

Phase 2a

Update